ReviewParasites & vectors2019
The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis.
Review in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- MicroRNAs during Echinococcus spp. infection: a comprehensive systematic review and implications for diagnosis and therapy.Parasites & vectors · 2026Pooled it
- Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni.PLoS neglected tropical diseases · 2024Article
- Stem cell-derived exosomes as a potential therapy for schistosomal hepatic fibrosis in experimental animals.Pathogens and global health · 2024Article
- Comprehensive analysis of miRNA profiling in Schistosoma mekongi across life cycle stages.Scientific reports · 2024Article
- Article
- Article
- MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets.Clinical microbiology reviews · 2023Review
- Can Echinococcus granulosus-Derived MicroRNAs be Biomarkers for Diagnosis and Follow-up of Cystic Echinococcosis Patients?Acta parasitologica · 2023Article
- microRNAs: Critical Players during Helminth Infections.Microorganisms · 2022Review
- Serum-derived miR-574-5p-containing exosomes contribute to liver fibrosis by activating hepatic stellate cells.Molecular biology reports · 2022Article
- Multifunctional Roles of MicroRNAs in Schistosomiasis.Frontiers in microbiology · 2022Review
- Highlighting the interplay of microRNAs fromParasitology · 2021Review
- MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7.Parasites & vectors · 2021Article
- Medical Imaging in the Diagnosis of Schistosomiasis: A Review.Pathogens (Basel, Switzerland) · 2021Review
- The Role of microRNAs in Cholangiocarcinoma.International journal of molecular sciences · 2021Review
- Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis.Parasites & vectors · 2021Article
- MiR-130a-3p Alleviates Liver Fibrosis by Suppressing HSCs Activation and Skewing Macrophage to Ly6CFrontiers in immunology · 2021Article
- Differential expression profiles of miRNAs and their putative targets in Schistosoma mansoni during its life cycle.Memorias do Instituto Oswaldo Cruz · 2021Article
- Human microRNAs in host-parasite interaction: a review.3 Biotech · 2020Review
- Post-genomic progress in helminth parasitology.Parasitology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Schistosomiasis is a prevalent parasitic disease worldwide. The main pathological changes of hepatosplenic schistosomiasis are hepatic granuloma and fibrosis due to worm eggs. Portal hypertension and ascites induced by hepatic fibrosis are usually the main causes of death in patients with chronic hepatosplenic schistosomiasis. Currently, no effective vaccine exists for preventing schistosome infections. For quite a long time, praziquantel (PZQ) was widely used for the treatment of schistosomiasis and has shown benefit in treating liver fibrosis. However, drug resistance and chemical toxicity from PZQ are being increasingly reported in recent years; therefore, new and effective strategies for treating schistosomiasis-induced hepatic fibrosis are urgently needed. MicroRNA (miRNA), a non-coding RNA, has been proved to be associated with the development of many human diseases, including schistosomiasis. In this review, we present a balanced and comprehensive view of the role of miRNAs in the pathogenesis, grading, and treatment of schistosomiasis-associated hepatic fibrosis. The multiple regulatory roles of miRNAs, such as promoting or inhibiting the development of liver pathology in murine schistosomiasis are also discussed in depth. Additionally, miRNAs may serve as candidate biomarkers for diagnosing liver pathology of schistosomiasis and as novel therapeutic targets for treating schistosomiasis-associated hepatic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.